SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018917
Filing Date
2023-11-14
Accepted
2023-11-14 08:15:55
Documents
81
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20230930x10q.htm   iXBRL 10-Q 2253500
2 EX-10.2 btai-20230930xex10d2.htm EX-10.2 268837
3 EX-31.1 btai-20230930xex31d1.htm EX-31.1 17385
4 EX-31.2 btai-20230930xex31d2.htm EX-31.2 17604
5 EX-32.1 btai-20230930xex32d1.htm EX-32.1 10365
6 EX-32.2 btai-20230930xex32d2.htm EX-32.2 8798
7 GRAPHIC btai-20230930x10q006.jpg GRAPHIC 78380
  Complete submission text file 0001558370-23-018917.txt   8651689

Data Files

Seq Description Document Type Size
8 EX-101.SCH btai-20230930.xsd EX-101.SCH 50752
9 EX-101.CAL btai-20230930_cal.xml EX-101.CAL 48128
10 EX-101.DEF btai-20230930_def.xml EX-101.DEF 210520
11 EX-101.LAB btai-20230930_lab.xml EX-101.LAB 497036
12 EX-101.PRE btai-20230930_pre.xml EX-101.PRE 379068
75 EXTRACTED XBRL INSTANCE DOCUMENT btai-20230930x10q_htm.xml XML 1259857
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 231401703
SIC: 2834 Pharmaceutical Preparations